These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8793009)

  • 21. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1989; 40(2):213-85. PubMed ID: 2543994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, hydrolytic behavior, and anti-HIV activity of selected acyloxyalkyl esters of trisodium phosphonoformate (foscarnet sodium).
    Iyer RP; Boal JH; Phillips LR; Thakker DR; Egan W
    J Pharm Sci; 1994 Sep; 83(9):1269-73. PubMed ID: 7530302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from Monostroma latissimum.
    Lee JB; Hayashi K; Hayashi T; Sankawa U; Maeda M
    Planta Med; 1999 Jun; 65(5):439-41. PubMed ID: 10418331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mode of action of phosphonoformate as an anti-herpes simplex virus agent.
    Cheng YC; Grill S; Derse D; Chen JY; Caradonna SJ; Connor K
    Biochim Biophys Acta; 1981 Jan; 652(1):90-8. PubMed ID: 6260189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the cytomegalovirus genome in the presence of PPi analogs.
    Wahren B; Rudén U; Gadler H; Oberg B; Eriksson B
    J Virol; 1985 Dec; 56(3):996-1001. PubMed ID: 2999452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation.
    Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Keefe KS; Bergeron-Lynn G; Severson GM; Soules KA; Mueller AJ; Freeman WR
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1523-32. PubMed ID: 10798672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and antiviral evaluation of 1-O-hexadecylpropanediol-3-P-acyclovir: efficacy against HSV-1 infection in mice.
    Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Rybak RJ; Kern ER; Hostetler KY
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):471-9. PubMed ID: 10772728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
    Griengl H; Hayden W; Penn G; De Clercq E; Rosenwirth B
    J Med Chem; 1988 Sep; 31(9):1831-9. PubMed ID: 2842506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses.
    Ayisi NK; Gupta SV; Babiuk LA
    Antiviral Res; 1985 Feb; 5(1):13-27. PubMed ID: 2984988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of cytomegalovirus late antigens by phosphonoformate.
    Wahren B; Oberg B
    Intervirology; 1980; 12(6):335-9. PubMed ID: 6244238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
    Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
    J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics.
    Dusserre N; Lessard C; Paquette N; Perron S; Poulin L; Tremblay M; Beauchamp D; Désormeaux A; Bergeron MG
    AIDS; 1995 Aug; 9(8):833-41. PubMed ID: 7576316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates.
    Charvet AS; Camplo M; Faury P; Graciet JC; Mourier N; Chermann JC; Kraus JL
    J Med Chem; 1994 Jul; 37(14):2216-23. PubMed ID: 8035429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents.
    Thomsen DR; Oien NL; Hopkins TA; Knechtel ML; Brideau RJ; Wathen MW; Homa FL
    J Virol; 2003 Feb; 77(3):1868-76. PubMed ID: 12525621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins.
    Camaioni Neto C; Steim JM; Sarin PS; Sun DK; Bhongle NN; Piratla RK; Turcotte JG
    Biochem Biophys Res Commun; 1990 Aug; 171(1):458-64. PubMed ID: 2144114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
    Sandstrom EG; Kaplan JC; Byington RE; Hirsch MS
    Lancet; 1985 Jun; 1(8444):1480-2. PubMed ID: 2409414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro inhibition of human herpesvirus-6 by phosphonoformate.
    Streicher HZ; Hung CL; Ablashi DV; Hellman K; Saxinger C; Fullen J; Salahuddin SZ
    J Virol Methods; 1988 Sep; 21(1-4):301-4. PubMed ID: 2972736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
    Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
    J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.
    Sullivan V; Coen DM
    J Infect Dis; 1991 Oct; 164(4):781-4. PubMed ID: 1654362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes.
    Szoka FC; Chu CJ
    Antimicrob Agents Chemother; 1988 Jun; 32(6):858-64. PubMed ID: 2843083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.